Filing Details

Accession Number:
0001104659-23-130499
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-29 16:30:27
Reporting Period:
2023-12-27
Accepted Time:
2023-12-29 16:30:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM Pharmaceutical Preparations (2834) 462159271
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1909855 Joseph Shulman 222 Berkeley Street, 12Th Floor
Boston MA 02116
Chief Technical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-27 2,400 $21.38 6,141 No 4 M Direct
Common Stock Disposition 2023-12-27 5,015 $50.01 1,126 No 4 S Direct
Common Stock Acquisiton 2023-12-28 6,800 $21.38 7,926 No 4 M Direct
Common Stock Disposition 2023-12-28 7,926 $50.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-12-27 2,400 $0.00 2,400 $21.38
Common Stock Stock Option (Right to Buy) Disposition 2023-12-28 6,800 $0.00 6,800 $21.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
82,600 2030-07-26 No 4 M Direct
75,800 2030-07-26 No 4 M Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.